Drugs / ZF2001
ZF2001
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05552573 | Jul 2022 → Jan 2023 | COVID-19 | Guangzhou Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04961359 | Jul → Dec 2021 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04445194 | Jun → Oct 2020 | Coronaviridae infectious disease | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05205096 | Nov 2021 → Jun 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT05205083 | Nov 2021 → Mar 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05109598 | Nov 2021 → Feb 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT04466085 | Jul → Oct 2020 | Coronaviridae infectious disease | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04646590 | Dec 2020 → Nov 2021 | — | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT04833101 | Apr → Sep 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05664932 Comparator | Dec 2022 → Jan 2023 | COVID-19 | Guangzhou Patronus Biotech Co., Ltd. | Unknown | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZF2001 | “The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was...” PMID 35507481 ↗ May 20227“Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV” NCT05205083 ↗ “Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac” NCT05205096 ↗ “The protein subunit vaccine ZF2001 appears to be well tolerated and immunogenic.” PMID 33773111 ↗ Mar 2021 “BACKGROUND: ZF2001 is a recombinant protein subunit vaccine against SARS-CoV-2” PMID 36803632 ↗ Feb 2023 “the SARS-CoV-2 RBD-based protein subunit vaccine (ZF2001, control group)” PMID 38695310 ↗ May 2024 |
| Known as | Recombinant new coronavirus vaccine (CHO cell) | “Product name: Recombinant new coronavirus vaccine (CHO cell),Each dose contains 25μgNCP-RBD protein/0.5mL/bottle.” NCT04961359 ↗ |
| Known as | Recombinant new coronavirus vaccine (CHO cells) | “Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).” NCT04961359 ↗ |
| Known as | Recombinant Novel Coronavirus Vaccine (CHO Cell) | “A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel...” NCT04646590 ↗ |
| Modality | Protein / enzyme biologic | “We developed a protein subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen.” PMID 33773111 ↗ Mar 2021 |
| Route | Intramuscular | “Intramuscular injection” NCT04445194 ↗ |